Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force
Pooled result · Hip fractureResult — go to the resultPooled relative risk 0.83 95% CI 0.73–0.93Authors' conclusion
Screening in higher-risk women 65 years or older was associated with a small absolute risk reduction in hip and major fractures compared with usual care.
Study context
- Population
- Older, higher-risk women (screening randomized clinical trials (RCTs)); primary osteoporosis (pharmacotherapy studies)3 RCTs (screening)
- Participants
- 42,009 participants
- Comparison
- Osteoporosis screening vs usual care; pharmacotherapy vs placebo
- Outcome
- Hip, clinical vertebral, major osteoporotic, and total fractures; mortality; harms; accuracy
Methodological detailsevidence review for the US Preventive Services Task Force, meta-analyses when at least 2 similar studies available, Two reviewers assessed studies and extracted data, Searches through January 9, 2024; surveillance through July 31, 2024
- Evidence review for the US Preventive Services Task Force
- Meta-analyses when at least 2 similar studies available
- Two reviewers assessed studies and extracted data
- Searches through January 9, 2024; surveillance through July 31, 2024
Pooled result
Hip fracture
Pooled relative risk
0.83
95% CI 0.73–0.93
Screeningvs Usual care
pooled RR 0.83 (95% CI 0.73–0.93)
As reported in the abstract
Further pooled results
| Outcome | Estimate | |
|---|---|---|
| Major osteoporotic fracture3 RCTs; 42 009 participants | pooled RR 0.94 (95% CI 0.88–0.99) | |
| Hip fracture with pharmacotherapyBisphosphonatesvs Placebo6 RCTs; 12 055 participants | pooled RR 0.67 (95% CI 0.45–1.00) | |
| Hip fracture with pharmacotherapyDenosumabvs PlaceboLargest RCT [7808 participants] | RR 0.60 (95% CI 0.37–0.97) | |
| 0.20.5125Ratio (log scale) |
Discriminative accuracy of risk assessment instruments for major osteoporotic fracture, hip fracture, or both
- Most had AUC between 0.60 and 0.80; varied by instrument and fracture type
- Calibration outcomes were limited
Safety
Adverse events with pharmacotherapy vs placebo
- No statistically significant associations observed
Original publication
Screening for Osteoporosis to Prevent Fractures: A Systematic Evidence Review for the US Preventive Services Task Force. JAMA. Published 11 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →